OncoQR ML

Executive Summary

OncoQR ML is a Vienna-based pre-clinical biotech startup founded in 2019, pioneering novel cancer immunotherapies through its proprietary S-TIR™ (Adjustable Cancer Immunotherapy) platform. The company's technology aims to fully harness the patient's immune system to combat cancer by engineering customizable immunotherapeutic agents. Despite being at an early stage, OncoQR ML's platform has potential applicability across multiple cancer types, leveraging a modular design that allows for tailored immune responses. The company operates as a platform licensor, seeking partnerships with larger pharmaceutical entities to advance its candidates into clinical development. With a lean structure and focus on preclinical validation, OncoQR ML represents a high-risk, high-reward opportunity in the immuno-oncology space. OncoQR ML's differentiation lies in its 'adjustable' platform, which theoretically could address limitations of fixed immunotherapies by allowing dynamic tuning of immune activity. The company has not disclosed specific financials, funding rounds, or detailed pipeline assets, but its presence in the biopharmguy directory suggests nascent commercialization efforts. Key milestones will be preclinical proof-of-concept data demonstrating the platform's versatility and safety profile. The company's success hinges on securing licensing deals or partnerships to fund IND-enabling studies and eventual clinical trials. Given the competitive immuno-oncology landscape, OncoQR ML must demonstrate clear advantages over existing modalities to attract collaborators and investors.

Upcoming Catalysts (preview)

• Q1 2027Release of preclinical efficacy data for lead S-TIR candidate70% success
• H2 2027Pharmaceutical licensing or co-development partnership30% success
• Q3 2026Series A financing round initiation50% success